Literature DB >> 17464290

Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis.

Ulrich B Keller1, Jennifer B Old, Frank C Dorsey, Jonas A Nilsson, Lisa Nilsson, Kirsteen H MacLean, Linda Chung, Chunying Yang, Charles Spruck, Kelli Boyd, Steven I Reed, John L Cleveland.   

Abstract

Reduced levels of the cyclin-dependent kinase inhibitor p27(Kip1) connote poor prognosis in cancer. In human Burkitt lymphoma and in precancerous B cells and lymphomas arising in Emu-Myc transgenic mice, p27(Kip1) expression is markedly reduced. We show that the transcription of the Cks1 component of the SCF(Skp2) complex that is necessary for p27(Kip1) ubiquitylation and degradation is induced by Myc. Further, Cks1 expression is elevated in precancerous Emu-Myc B cells, and high levels of Cks1 are also a hallmark of Emu-Myc lymphoma and of human Burkitt lymphoma. Finally, loss of Cks1 in Emu-Myc B cells elevates p27(Kip1) levels, reduces proliferation and markedly delays lymphoma development and dissemination of disease. Therefore, Myc suppresses p27(Kip1) expression, accelerates cell proliferation and promotes tumorigenesis at least in part through its ability to selectively induce Cks1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17464290      PMCID: PMC1868903          DOI: 10.1038/sj.emboj.7601691

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  65 in total

1.  p27 destruction: Cks1 pulls the trigger.

Authors:  J Bartek; J Lukas
Journal:  Nat Cell Biol       Date:  2001-04       Impact factor: 28.824

2.  A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1.

Authors:  C Spruck; H Strohmaier; M Watson; A P Smith; A Ryan; T W Krek; S I Reed
Journal:  Mol Cell       Date:  2001-03       Impact factor: 17.970

Review 3.  Proliferation, cell cycle and apoptosis in cancer.

Authors:  G I Evan; K H Vousden
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

4.  Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis.

Authors:  C M Eischen; D Woo; M F Roussel; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 5.  The myc oncogene: MarvelouslY Complex.

Authors:  Sara K Oster; Cynthia S W Ho; Erinn L Soucie; Linda Z Penn
Journal:  Adv Cancer Res       Date:  2002       Impact factor: 6.242

6.  c-Myc regulates mammalian body size by controlling cell number but not cell size.

Authors:  A Trumpp; Y Refaeli; T Oskarsson; S Gasser; M Murphy; G R Martin; J M Bishop
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

7.  A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase.

Authors:  N P Malek; H Sundberg; S McGrew; K Nakayama; T R Kyriakides; J M Roberts; T R Kyriakidis
Journal:  Nature       Date:  2001-09-20       Impact factor: 49.962

Review 8.  Translocations involving c-myc and c-myc function.

Authors:  L M Boxer; C V Dang
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

9.  Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma.

Authors:  Ma'anit Shapira; Ofer Ben-Izhak; Bishara Bishara; Boris Futerman; Ira Minkov; Michael M Krausz; Michele Pagano; Dan D Hershko
Journal:  Cancer       Date:  2004-04-15       Impact factor: 6.860

10.  Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis.

Authors:  Carla P Martins; Anton Berns
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

View more
  48 in total

1.  p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs.

Authors:  Tulsiram Prathapam; Alexey Aleshin; Yinghui Guan; Joe W Gray; G Steven Martin
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

2.  Distinct roles for p107 and p130 in Rb-independent cellular senescence.

Authors:  Brian D Lehmann; Adam M Brooks; Matthew S Paine; William H Chappell; James A McCubrey; David M Terrian
Journal:  Cell Cycle       Date:  2008-03-07       Impact factor: 4.534

3.  Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.

Authors:  Kamonwan Fish; Jia Chen; Richard Longnecker
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

4.  Gene expression signature of c-MYC-immortalized human fibroblasts reveals loss of growth inhibitory response to TGFβ.

Authors:  Myra L Wang; Ryan Walsh; Kristin L Robinson; Julja Burchard; Steven R Bartz; Michele Cleary; Denise A Galloway; Carla Grandori
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

5.  Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.

Authors:  Alexander Hoellein; Mohammad Fallahi; Stephanie Schoeffmann; Sabine Steidle; Franz X Schaub; Martina Rudelius; Iina Laitinen; Lisa Nilsson; Andrei Goga; Christian Peschel; Jonas A Nilsson; John L Cleveland; Ulrich Keller
Journal:  Blood       Date:  2014-08-20       Impact factor: 22.113

6.  Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the Myc gene to facilitate lytic replication.

Authors:  Hye-Ra Lee; Sultan Doğanay; Brian Chung; Zsolt Toth; Kevin Brulois; Stacy Lee; Zhansaya Kanketayeva; Pinghui Feng; Taekjip Ha; Jae U Jung
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

7.  NHERF-2 maintains endothelial homeostasis.

Authors:  Resham Bhattacharya; Enfeng Wang; Shamit K Dutta; Pawan K Vohra; Guangqi E; Y S Prakash; Debabrata Mukhopadhyay
Journal:  Blood       Date:  2012-02-17       Impact factor: 22.113

8.  CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis.

Authors:  Yuanzhi Lu; Yongsheng Wu; Xiaoling Feng; Rulong Shen; Jing H Wang; Mohammad Fallahi; Weimin Li; Chunying Yang; William Hankey; Weiqiang Zhao; Ramesh K Ganju; Ming O Li; John L Cleveland; Xianghong Zou
Journal:  J Clin Invest       Date:  2014-03-10       Impact factor: 14.808

9.  Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.

Authors:  Robert J Rounbehler; Weimin Li; Mark A Hall; Chunying Yang; Mohammad Fallahi; John L Cleveland
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

10.  ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.

Authors:  Michael D Hogarty; Murray D Norris; Kimberly Davis; Xueyuan Liu; Nicholas F Evageliou; Candace S Hayes; Bruce Pawel; Rong Guo; Huaqing Zhao; Eric Sekyere; Joanna Keating; Wayne Thomas; Ngan Ching Cheng; Jayne Murray; Janice Smith; Rosemary Sutton; Nicola Venn; Wendy B London; Allen Buxton; Susan K Gilmour; Glenn M Marshall; Michelle Haber
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.